These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30034521)

  • 1. The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Ecancermedicalscience; 2018; 12():844. PubMed ID: 30034521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
    Murray NP; Aedo S; Reyes E; Fuentealba C; Jacob O
    Ecancermedicalscience; 2016; 10():671. PubMed ID: 27610197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How localized is pathologically localized prostate cancer? The use of secondary circulating prostate cells as a marker of minimal residual disease and their association with patient outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Turk J Urol; 2017 Dec; 43(4):456-461. PubMed ID: 29201508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Bádinez L; Olivares R; Porcell J; Dueñas R
    ScientificWorldJournal; 2013; 2013():762064. PubMed ID: 23653529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O
    J Oncol; 2014; 2014():612674. PubMed ID: 25210517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.